Patient characteristics (n=1666) at the time of initial evaluation stratified according to pacemaker status after completed syncope workup. Patients with previous pacemaker were excluded
| Patients with new pacemaker (n=106) | Patients without pacemaker (n=1560) | P value | |
| Age, years | 65.5 (16.8) | 50.9 (21.8) | <0.001 |
| Sex, % female | 45.3 | 61.8 | <0.001 |
| Reported history of | |||
| Syncope, % | 98.1 | 91.0 | 0.014 |
| Dizziness, n % | 68.3 | 72.9 | NS |
| Number of syncope episodes, md (range) | 7 (0–100) | 4 (0–1350 | NS |
| Duration of symptoms, years, md (range) | 7 (0–70) | 3 (0–77) | <0.001 |
| SBP, mm Hg | 139.1 (22.2) | 130.9 (22.4) | <0.001 |
| DBP, mm Hg | 71.4 (10.5) | 71.6 (10.2) | NS |
| Resting heart rate, bpm | 66.3 (11.6) | 70.5 (12.6) | <0.001 |
| eGFR, mL/min | 79.3 (27.8) | 96.4 (35.6) | <0.001 |
| EF, % | 54 (3) | 54 (3) | 0.418 |
| Hypertension, % | 39.4 | 27.8 | 0.011 |
| Antihypertensive therapy, % | 39.8 | 33.4 | 0.185 |
| ACE inhibitors | 10.7 | 9.6 | 0.721 |
| ARB | 16.5 | 9.2 | 0.014 |
| Thiazides | 10.7 | 6.4 | 0.090 |
| Beta blockers* | 14.6 | 18.5 | 0.322 |
| CAD, % | 7.8 | 6.3 | NS |
| Atrial fibrillation, % | 10.4 | 6.3 | NS |
| Heart failure, % | 6.8 | 3.1 | <0.001 |
*Beta blockers were discontinued prior to the examination.
ARB, angiotensin II receptor blockers;CAD, coronary artery disease; DBP, diastolic blood pressure;EF, ejection fraction;eGFR, estimated glomerular filtration rate;SBP, systolic blood pressure.